Valneva (NASDAQ:VALN) Shares Up 3.9% – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN) shares traded up 3.9% during mid-day trading on Wednesday. The company traded as high as $5.73 and last traded at $5.7780. 2,831 shares changed hands during trading, a decline of 95% from the average daily volume of 61,432 shares. The stock had previously closed at $5.56.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on VALN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research note on Monday, September 14th. TD Cowen assumed coverage on shares of Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 target price for the company. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Valneva presently has an average rating of “Reduce” and a consensus target price of $9.30.

Valneva Trading Up 4.4%

The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The firm has a market cap of $560.80 million, a price-to-earnings ratio of -2.80 and a beta of 1.53. The firm’s fifty day moving average is $6.35 and its 200-day moving average is $5.82.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. The business had revenue of $39.37 million for the quarter, compared to analyst estimates of $44.17 million. Equities analysts anticipate that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current year.

Valneva Company Profile

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.